Therapeutic Preferences for Coronavirus 2 (SARS-CoV-2) Patients

Author:
Dr. Nasir Mustafa
(Istanbul Gelisim University)
nasirmustafaspan@gmail.com
nmustafa@gelisim.edu.tr
orcid.org/0000-0002-5821-9297
ABSTRACT:

Background:
Modern researches have focused the attention towards the potential advantage of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel appeared coronavirus (SARS-CoV-2). Chloroquine/hydroxychloroquine has been frequently used in treating SARS-CoV-2 infection. Which is useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. The scientific community should consider this information in light of previous experiments with Chloroquine/hydroxychloroquine in the field of antiviral research.

Methods:
In the view of current situation efforts of international health professionals have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. It is mandatory to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2. Since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.

Results:
Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine/hydroxychloroquine can improve the clinical outcome of patients infected by SARS-CoV-2.

Keywords: SARS-CoV-2, COVID-19, 2019-nCoV, Antiviral, Hydroxychloroquine.
Background

Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available. Severe acute respiratory syndrome (SARS) is an emerging disease that was first reported in Guangdong Province, China, in late 2002. The disease rapidly spread to at least 30 countries within months of its first appearance, and concerted worldwide efforts led to the identification of the etiological agent as SARS coronavirus (SARS-CoV), a novel member of the family Coronaviridae. Complete genome sequencing of SARS-CoV confirmed that this pathogen is not closely related to any of the previously established coronavirus groups. Budding of the SARS-CoV occurs in the Golgi apparatus and results in the incorporation of the envelope spike glycoprotein into the virion. Due to the severity of SARS-CoV infection, the potential for rapid spread of the disease, and the absence of proven effective and safe in vivo inhibitors of the virus, it is important to identify drugs that can effectively be used to treat or prevent potential SARS-CoV infections. Many novel therapeutic approaches have been evaluated in laboratory studies of SARS-CoV: notable among these approaches are those using RNA, passive antibody transfer, DNA vaccination, vaccinia or parainfluenza virus expressing the spike protein, interferons, and monoclonal antibody to the S1-subunit of the spike glycoprotein that blocks receptor binding. This report, we describe that identification of chloroquine as an effective pre- and post-infection antiviral agent for SARS-CoV.

Introduction

Antimalarial drugs with the 4-aminoquinoline scaffold such as the important drugs, chloroquine and hydroxychloroquine, have been used to prevent and treat malaria for many years. Chloroquine is an amine acidotropic form of quinine that was synthesized in Germany by Bayer in 1934 and emerged approximately 70 years ago as an effective substitute for natural quinine [1,2]. Quinine is a compound found in the bark of Cinchona trees native to Peru and was the previous drug of choice against malaria [3]. For decades, chloroquine was a front-line drug for the treatment and prophylaxis of malaria and is one of the most prescribed drugs worldwide [4]. Chloroquine and the 4-aminoquinoline drug hydroxychloroquine belong to the same molecular family. Hydroxychloroquine differs from chloroquine by the presence of a hydroxyl group at the end of the side chain: the N-ethyl substituent is β-hydroxylated. This molecule is available for oral administration in the form of hydroxychloroquine sulfate. Hydroxychloroquine has
pharmacokinetics similar to that of chloroquine, with rapid gastrointestinal absorption and renal elimination. However, the clinical indications and toxic doses of these drugs slightly differ. In malaria, the indication for chloroquine was a high dose for a short period of time (due to its toxicity at high doses) or a low dose for a long period of time. Hydroxychloroquine was reported to be as active as chloroquine against *Plasmodium falciparum* malaria and less toxic, but it is much less active than chloroquine against chloroquine-resistant *P. falciparum* owing to its physicochemical properties. What is advantageous with hydroxychloroquine is that it can be used in high doses for long periods with very good tolerance. Unfortunately, the efficacy of chloroquine gradually declined due to the continuous emergence of chloroquine-resistant *P. falciparum* strains [5]. Chloroquine is also utilised in the treatment of autoimmune diseases [6]. Yet the activity of the molecule is not limited to malaria and the control of inflammatory processes, as illustrated by its broad-spectrum activity against a range of bacterial, fungal and viral infections [7–10]. Indeed, in the mid-1990s, due to its tolerability, rare toxicity reports, inexpensive cost and immunomodulatory properties [11], chloroquine repurposing was explored against human immunodeficiency virus (HIV) and other viruses associated with inflammation and was found to be efficient in inhibiting their replication cycle [12]. Recently, a novel coronavirus emerged in the Chinese city of Wuhan in December 2019. After human coronavirus 229E (HCoV-229E) (classified in the genus *Alphacoronavirus*) and HCoV-OC43 (*Betacoronavirus* lineage 2a member) described in the 1960s, SARS-CoV-1 (*Betacoronavirus* lineage 2b member) that emerged in March 2003, HCoV-NL63 (*Alphacoronavirus* lineage 1b member) described in 2004, HCoV-HKU1 (*Betacoronavirus* lineage 2a member) discovered in 2005, and finally MERS-CoV that emerged in 2012 (classified in *Betacoronavirus* lineage 2c), the novel coronavirus is the seventh human coronavirus described to date as being responsible for respiratory infection. Evidence was rapidly reported that patients were suffering from an infection with a novel *Betacoronavirus* tentatively named 2019 novel coronavirus (2019-nCoV) [13,14]. Despite drastic containment measures, the spread of 2019-nCoV, now officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is ongoing. Phylogenetic analysis of this virus indicated that it is different (80% nucleotide identity) but related to SARS-CoV-1 [15]. Because the world is threatened by the possibility of a SARS-CoV-2 pandemic, the broad-spectrum antiviral effects of chloroquine warranted particular attention for repurposing this drug in the therapy of the disease caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19).
Antiviral Role of Chloroquine

In vitro, chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [16], poliovirus [17], HIV [12,18–20], hepatitis A virus [21,22], hepatitis C virus [23], influenza A and B viruses [24–27], influenza A H5N1 virus [28], Chikungunya virus [29–31], Dengue virus [32,33], Zika virus [34], Lassa virus [35], Hendra and Nipah viruses [36,37], Crimean–Congo hemorrhagic fever virus [38] and Ebola virus [39], as well as various DNA viruses such as hepatitis B virus [40] and herpes simplex virus [41]. The antiviral properties of chloroquine described in vitro have sometimes been confirmed during treatment of virus-infected patients but have not always been reproduced in clinical trials depending on the disease, the concentration of chloroquine used, the duration of treatment and the clinical team in charge of the trial. Regarding coronaviruses, the potential therapeutic benefits of chloroquine were notably reported for SARS-CoV-1 [11,42]. Chloroquine was also reported to inhibit in vitro the replication of HCoV-229E in epithelial lung cell cultures [43,44]. In 2009, it was reported that lethal infections of newborn mice with the HCoV-O43 coronavirus could be averted by administering chloroquine through the mother’s milk. In vitro experiments also showed a strong antiviral effect of chloroquine on a recombinant HCoV-O43 coronavirus [45]. Although chloroquine was reported to be active against Middle East respiratory syndrome coronavirus (MERS-CoV) in vitro [46], this observation remains controversial [47].

Action of chloroquine against SARS-CoV-2

Because of its broad spectrum of action against viruses, including most coronaviruses and particularly its close relative SARS-CoV-1, and because coronavirus cell entry occurs through the endolysosomal pathway [48], it made sense in a situation of a public-health emergency and the absence of any known efficient therapy to investigate the possible effect of chloroquine against SARS-CoV2. A recent paper reported that both chloroquine and the antiviral drug remdesivir inhibited SARS-CoV-2 in vitro and suggested these drugs be assessed in human patients suffering from COVID-19 [49]. Recently, the China National Center for Biotechnology Development indicated that chloroquine is one of the three drugs with a promising profile against the new SARS-CoV-2 coronavirus that causes COVID-19. Chloroquine repurposing was investigated in hospitals in Beijing, in central China’s Hunan Province and South China’s Guangdong Province. According to preliminary reports [50,51] from the Chinese authorities suggesting that
approximately 100 infected patients treated with chloroquine experienced a more rapid decline in fever and improvement of lung computed tomography (CT) images and required a shorter time to recover compared with control groups, with no obvious serious adverse effects, the Chinese medical advisory board has suggested chloroquine inclusion in the SARS-CoV-2 treatment guidelines. As a result, chloroquine is probably the first molecule to be used in China and abroad on the front line for the treatment of severe SARS-CoV-2 infections. Although the long use of this drug in malaria therapy demonstrates the safety of acute chloroquine administration to humans, one cannot ignore the minor risk of macular retinopathy, which depends on the cumulative dose [52], and the existence of some reports on cardiomyopathy as a severe adverse effect caused by chloroquine [53,54]. A survey of SARS-CoV-2-infected patients for adverse effects of chloroquine therapy remains to be performed. However, chloroquine is currently among the best available candidates to impact the severity of SARS-CoV-2 infections in humans. Currently, at least ten clinical trials are testing chloroquine as an anti-COVID-19 therapy [55].

**Mechanism of action of Chloroquine**

Chloroquine has multiple mechanisms of action that may differ according to the pathogen studied. Chloroquine can inhibit a pre-entry step of the viral cycle by interfering with viral particles binding to their cellular cell surface receptor. Chloroquine was shown to inhibit quinone reductase 2 [56], a structural neighbour of UDP-N-acetylglucosamine 2-epimerases [57] that are involved in the biosynthesis of sialic acids. The sialic acids are acidic monosaccharides found at the extremity of sugar chains present on cell transmembrane proteins and are critical components of ligand recognition. The possible interference of chloroquine with sialic acid biosynthesis could account for the broad antiviral spectrum of that drug since viruses such as the human coronavirus HCoV-O43 and the orthomyxoviruses use sialic acid moieties as receptors [58]. The potent anti-SARS-CoV-1 effects of chloroquine in vitro were considered attributable to a deficit in the glycosylation of a virus cell surface receptor, the angiotensin-converting enzyme 2 (ACE2) on Vero cells [59]. Chloroquine can also impair another early stage of virus replication by interfering with the pH-dependent endosome-mediated viral entry of enveloped viruses such as Dengue virus or Chikungunya virus [60,61]. Due to the alkalisation of endosomes, chloroquine was an effective in vitro treatment against Chikungunya virus when added to Vero cells prior to virus exposure [30]. The mechanism of inhibition likely involved the prevention of endocytosis and/or rapid elevation
of the endosomal pH and abrogation of virus–endosome fusion. A pH-dependant mechanism of entry of coronavirus into target cells was also reported for SARS-CoV-1 after binding of the DC-SIGN receptor [62]. The activation step that occurs in endosomes at acidic pH results in fusion of the viral and endosomal membranes leading to the release of the viral SARS-CoV-1 genome into the cytosol [63]. In the absence of antiviral drug, the virus is targeted to the lysosomal compartment where the low pH, along with the action of enzymes, disrupts the viral particle, thus liberating the infectious nucleic acid and, in several cases, enzymes necessary for its replication [64]. Chloroquine mediated inhibition of hepatitis-A virus was found to be associated with uncoating, thus blocking its entire replication cycle [22]. Chloroquine can also interfere with the post-translational modification of viral proteins. These post-translational modifications, which involve proteases and glycosyltransferases, occur within the endoplasmic reticulum or the trans-Golgi network vesicles and may require a low pH. For HIV, the antiretroviral effect of chloroquine is attributable to a post-transcriptional inhibition of glycosylation of the gp120 envelope glycoprotein, and the neosynthesised virus particles are noninfectious [19,65]. Chloroquine also inhibits the replication Dengue-2 virus by affecting the normal proteolytic processing of the flavivirus prM protein to M protein [32]. As a result, viral infectivity is impaired. In the herpes simplex virus (HSV) model, chloroquine inhibited budding with accumulation of non-infectious HSV-1 particles in the trans-Golgi network [66]. Using non-human coronavirus, it was shown that the intracellular site of coronavirus budding is determined by the localization of its membrane M proteins that accumulate in the Golgi complex beyond the site of virion budding [67], suggesting a possible action of chloroquine on SARS-CoV-2 at this step of the replication cycle. It was recently reported that the C-terminal domain of the MERS-CoV M protein contains a trans-Golgi network localization signal [68]. Besides affecting the virus maturation process, pH modulation by chloroquine can impair the proper maturation of viral protein [32] and the recognition of viral antigen by dendritic cells, which occurs through a Toll-like receptor-dependent pathway that requires endosomal acidification [69]. On the contrary, other proposed effects of chloroquine on the immune system include increasing the export of soluble antigens into the cytosol of dendritic cells and the enhancement of human cytotoxic CD8+ Tcell responses against viral antigens [70]. In the influenza virus model, it was reported that chloroquine improve the cross-presentation of non-replicating virus antigen by dendritic cells to CD8+ T-cells recruited to lymph nodes draining the site of infection, eliciting a broadly protective immune response [71]. Chloroquine can also act
on the immune system through cell signalling and regulation of pro-inflammatory cytokines. Chloroquine is known to inhibit phosphorylation (activation) of the p38 mitogen-activated protein kinase (MAPK) in THP-1 cells as well as caspase-1 [72]. Activation of cells via MAPK signalling is frequently required by viruses to achieve their replication cycle [73]. In the model of HCoV-229 coronavirus, chloroquine-induced virus inhibition occurs through inhibition of p38 MAPK [44]. Chloroquine is a well-known immunomodulatory agent capable of mediating an anti-inflammatory response [11]. Therefore, there are clinical applications of this drug in inflammatory diseases such as rheumatoid arthritis [74–76], lupus erythematosus [6,77] and sarcoidosis [78]. Chloroquine inhibits interleukin-1 beta (IL-1β) mRNA expression in THP-1 cells and reduces IL-1β release [72]. Chloroquine-induced reduction of IL-1 and IL-6 cytokines was also found in monocytes/macrophages [79]. Chloroquine-induced inhibition of tumor necrosis factor-alpha (TNFα) production by immune cells was reported to occur either through disruption of cellular iron metabolism [80], blockade of the conversion of pro-TNF into soluble mature TNFα molecules [81] and/or inhibition of TNFα mRNA expression [72,82,83]. Inhibition of the TNFα receptor was also reported in U937 monocyctic cells treated with chloroquine [84]. In the Dengue virus model, chloroquine was found to inhibit interferon-alpha (IFNα, IFNβ, IFNγ, TNFα, IL-6 and IL-12 gene expression in U937 cells infected with Dengue-2 virus [33].

**Methods:**

In the view of current situation efforts of international health professionals have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. It is mandatory to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2. Since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.
Results:
Chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine/hydroxychloroquine can improve the clinical outcome of patients infected by SARS-CoV-2.

Discussion
Modern research have brought attention to the possible advantage of chloroquine, a broadly used antimalarial drug, in the management of patients infected by the novel developed coronavirus (SARS-CoV-2) [85]. The scientific community should consider this evidence in view of previous experiments with Hydroxychloroquine in the area of antiviral research. The sulfate and phosphate salts of chloroquine have both been available as antimalarial drugs. Hydroxychloroquine has also been used as an antimalarial, but in addition is now broadly used in autoimmune diseases such as lupus and rheumatoid arthritis. Although chloroquine and Hydroxychloroquine are considered to be safe and side-effects are generally mild and transitory [86]. Chloroquine and hydroxychloroquine use should therefore be subject to strict rules, and self-treatment is not recommended. The in vitro antiviral activity of hydroxychloroquine has been identified since the late 1960's [87] and the growth of many different viruses can be inhibited in cell culture by both chloroquine and hydroxychloroquine, including the SARS coronavirus [88]. However, chloroquine did not prevent influenza infection in a randomized, double-blind, placebo-controlled clinical trial [89], and had no effect on dengue-infected patient in a randomized controlled trial in Vietnam [90]. Hydroxychloroquine was also active ex vivo but not in vivo in the case of ebolavirus in mice [91], in ferrets. The case of chikungunya virus (CHIKV) is of specific interest: Hydroxychloroquine showed promising antiviral activity in vitro [92], but was shown to enhance alphavirus replication in various animal models, most probably because of the immune modulation and anti-inflammatory properties of Hydroxychloroquine in vivo. In a nonhuman primate model of CHIKV infection, Hydroxychloroquine treatment was shown to aggravate acute fever and delay the cellular immune response, leading to an incomplete viral clearance [93]. A clinical trial conducted during the chikungunya outbreak in 2006 in Reunion Island indicated that oral Hydroxychloroquine treatment did not recover the course of the acute disease and that chronic arthralgia on day 300 post illness was more frequent in treated patients than in the control group.
Overall, the assessment of previous trials indicates that, to date, no acute virus infection has been successfully treated by Hydroxychloroquine in humans. Hydroxychloroquine has also been tested in chronic viral diseases. Its use in the treatment of HIV-infected patients has been considered inconclusive [95] and the drug has not been included in the panel recommended for HIV treatment. Recently FDA-approved drugs and two broad spectrum antivirals against a clinical isolate of SARS-CoV-2. One of their conclusions was that "Hydroxychloroquine (is) highly effective in the control of 2019-nCoV infection in vitro" and that it’s "safety track record suggests that it should be evaluated in human patients suffering from the novel coronavirus disease". At least 16 different trials for SARS-CoV-2 already registered to use Hydroxychloroquine or Hydroxychloroquine in the treatment of COVID-19 "Chinese Clinical Trial Register" (ChiCTR). In a recent publication [96], researchers indicate that, "according to the news briefing", "results from more than 100 patients have established that Hydroxychloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course". This would represent the first successful practice of Hydroxychloroquine in humans for the treatment of an acute viral disease, and is undoubtedly excellent news, since this drug is cheap and widely available. However, it should be considered carefully before drawing definitive conclusions, since no data has been provided yet to support this declaration. Results were produced in ten different hospitals and possibly from a number of different clinical protocols among those listed above, which include various designs for control groups (none, different antivirals, placebo, etc.) and various outcome primary indicators. The final interpretation is therefore technically demanding, and in the absence of published data, it is difficult to reach any secure conclusion. It will be of the greatest importance to know if the experiential efficacy is associated specifically with Hydroxychloroquine phosphate, or if this includes other salts (e.g., sulfate) of Hydroxychloroquine, and hydroxychloroquine. It is also compulsory to determine if the benefit of hydroxychloroquine therapy depends on the age class, the clinical presentation or the stage of the disease. In conclusion, the option of using hydroxychloroquine in the treatment of SARS-CoV-2 should be observed with attention in light of the recent promising announcements, but also of the potential detrimental effect of the drug detected in previous attempts to treat acute viral diseases.
CONCLUSION:

Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine and hydroxychloroquine can improve the clinical outcome of patients infected by SARS-CoV-2. The multiple molecular mechanisms by which chloroquine can achieve such results remain to be further explored. Since SARS-CoV-2 was found a few days ago to utilize the same cell surface receptor ACE2 (expressed in lung, heart, kidney and intestine) as SARS-CoV-1 [96,97] (Table 1), it may be hypothesised that chloroquine also interferes with ACE2 receptor glycosylation thus preventing SARS-CoV-2 binding to target cells. Wang and Cheng reported that SARS-CoV and MERS-CoV upregulate the expression of ACE2 in lung tissue, a process that could accelerate their replication and spread [96]. Although the binding of SARS-CoV to sialic acids has not been reported so far (it is expected that Betacoronavirus adaptation to humans involves progressive loss of hemagglutinin-esterase lectin activity), if SARS-CoV-2 like other coronaviruses targets sialic acids on some cell subtypes, this interaction will be affected by chloroquine treatment [98,99].

Today, preliminary data indicate that chloroquine interferes with SARS-CoV-2 attempts to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein [100], a prerequisite to the formation of the autophagosome [60]. Obviously, it can be hypothesized that SARS-CoV-2 molecular crosstalk with its target cell can be altered by chloroquine through inhibition of kinases such as MAPK. Chloroquine could also interfere with proteolytic processing of the M protein and alter virion assembly and budding (Fig. 1). Finally, in COVID-19 disease this drug could act indirectly through reducing the production of proinflammatory cytokines or by activating anti-SARS-CoV-2 CD8+ T-cells. As the world's health experts race to find treatments and eventually, a cure for the novel coronavirus, two drugs have jumped to the front of the conversation chloroquine and hydroxychloroquine. The side effects include seizures, nausea, vomiting, deafness, vision changes and low blood pressure. Hydroxychloroquine has very noteworthy advantages as a prime candidate for antiviral prophylaxis against the current COVID-19 pandemic where no current vaccine or antiviral prophylaxis is in place. Its established mechanisms of action of preventing viral entry and fusion, sign of in vitro efficacy at clinically recommended doses, high tissue concentration as well as preliminary clinical proof of efficacy as treatment all provision its promising preventative part. Its safety record and low cost at doses we suggest indicate a high potential advantage to risk and
benefit to cost ratio when used for prophylaxis. We need relevant agencies to consider initiating trials as well as prepare for direct mass distribution of a hydroxychloroquine based COVID-19 preventative program without undue delay. One drug, lopinavir-ritonavir, did not show promise for treating Covid-19-related pneumonia in China. But another drug Remdesivir, has "broad antiviral activity,"

**Abbreviations**

**SARS**: Severe acute respiratory syndrome  
**CoV-2**: Coronavirus type 2  
**COVID**: Coronavirus disease  
**nCoV**: Novel Coronavirus  
**P. falciparum**: Plasmodium falciparum  
**HIV**: Human immunodeficiency virus  
**HKU1**: Human coronavirus 1  
**MERS**: Middle East Respiratory Syndrome  
**UDP**: Uridine diphosphate  
**ACE2**: Angiotensin-converting enzyme 2  
**HSV**: Herpes simplex virus  
**MAPK**: Mitogen-activated protein kinase  
**TNF**: Tumor necrosis factor  
**CHIKV**: Chikungunya virus

- **DECLARATION SECTION**
  - **Ethical Approval and Consent to participate**  Not required.
  - **Consent for publication**  “Not applicable”
  - **Availability of supporting data**  “Not applicable”
  - **Competing interests**  The author(s) declare that they have no competing interests.
  - **Funding**  “None”
  - **Authors’ contributions**  “Not applicable”
  - **Acknowledgements**  The figure was designed using the Servicer Medical Art supply of images available under a Creative Commons CC BY 3.0 license.
- Authors’ information

Name: Nasir Mustafa
Title: Assistant Professor
Email: nasirmustafaspan@gmail.com
nmustafa@gelisim.edu.tr
Telephone +905537931731

References

[1] Most, H. (1964). The Pendulum in Malaria Chemotherapy: From Quinine to Chloroquine and Back to Quinine? Military Medicine, 129(7), 587-590. https://doi.org/10.1093/milmed/129.7.587

[2] Amodiaquine has Greater Antimalarial Effect than Chloroquine in Kenya. (1984). InPharma, 441(1), 11-11. https://doi.org/10.1007/bf03315590

[3] Sullivan, D. J. (2011). Cinchona Alkaloids: Quinine and Quinidine. Treatment and Prevention of Malaria, 45-68. https://doi.org/10.1007/978-3-0346-0480-2_3

[4] White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet 2014;383:723–35. doi: 10.1016/S0140-6736(13)60024-0.

[5] Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001;184:770–6.

[6] Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718–29. doi: 10.1038/nrneph.2011.150.

[7] Raoult D, Drancourt M, Vestris G. Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 1990;34:1512–4. doi: 10.1128/aac.34.8.1512.

[8] Raoult D, Houpikian P, Tissot DH, Riss JM, Arditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med 1999;159:167–73. doi: 10.1001/archinte.159.2.167.

[9] Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whippelii in MRC5 cells. Antimicrob Agents Chemother 2004;48:747–52.

[10] Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century. Int J Antimicrob Agents 2007;30:297–308.

[11] Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003;3:722–7.
[12] Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol 2001;20:137–40.

[13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.

[14] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.

[15] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020 Jan 23. doi: 10.1101/2020.01.22.914952.

[16] Tsiang H, Superti F. Ammonium chloride and chloroquine inhibit rabies virus infection in neuroblastoma cells. Arch Virol 1984;81:377–82.

[17] Kronenberger P, Vrijser R, Boeyé A. Chloroquine induces empty capsid formation during poliovirus eclipse. J Virol 1991;65:7008–11.

[18] Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Human Retroviruses 1990;6:481–9. doi: 10.1089/aid.1990.6.481.

[19] Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. J Clin Virol 2001;20:131–5.

[20] Romanelli F, Smith KM, Hoven AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 2004;10:2643–8.

[21] Superti F, Seganti L, Orsi W, Divizia M, Gabrieli R, Pana A. The effect of lipophilic amines on the growth of hepatitis A virus in Frp/3 cells. Arch Virol 1987;96:289–96. doi: 10.1007/bf01320970.

[22] Bishop NE. Practical guidelines in antiviral therapy. Intervirology 1998;41:261–71.

[23] Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 2010;45:195–203.

[24] Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc Natl Acad Sci U S A 1981;78:3605–9. doi: 10.1073/pnas.78.6.3605.

[25] Shibata M, Aoki H, Tsurumi T, Sugiura Y, Nishiyama Y, Suzuki S, et al. Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine. J Gen Virol 1983;64:1149–56. doi: 10.1099/0022-1317-64-5-1149.
[26] Ooi EE, Chew JS, Loh JP, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006;3:39.

[27] Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis 2011;11:677–83.

[28] Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013;23:300–2. doi: 10.1038/cr.2012.165.

[29] De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, et al. On Chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008;8:837–40. doi: 10.1089/vbz.2008.0049.

[30] Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in Vero cells. J Med Virol 2010;82:817–24.

[31] Delogu I, de Lamballerie X. Chikungunya disease and chloroquine treatment. J Med Virol 2011;83:1058–9.

[32] Randolph VB, Winkler G, Stollar V. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 1990;174:450–8. doi: 10.1016/0042-6822(90)90099-d.

[33] Farias KJ, Machado PR, de Almeida Junior RF, da Fonseca AA, da Fonseca BA. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol 2014;58:318–26.

[34] Delvecchio R, Higa LM, Pezzuto P, Valadao AL, Garcez PP, Monteiro FL, et al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 2016;8:E322. doi: 10.3390/v8120322.

[35] Glushakova SE, Lukashevich IS. Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch Virol 1989;104:157–61.

[36] Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, et al. Simulating Henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol 2009;83:5148–55.

[37] Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol 2010;91:765–72. doi: 10.1099/vir.0.017269-0.

[38] Ferraris O, Moroso M, Pernet O, Emonet S, Ferrier Rembert A, Paranhos-Baccala G, et al. Evaluation of Crimean–Congo hemorrhagic fever virus in vitro inhibition by chloroquine and
chlorpromazine, two FDA approved molecules. Antiviral Res 2015;118:75–81. doi: 10.1016/j.antiviral.2015.03.005.

[39] Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 2015;96:3484–92.

[40] Kouroumalis EA, Koskinas J. Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report. Ann Acad Med Singapore 1986;15:149–52.

[41] Koyama AH, Uchida T. Inhibition of multiplication of herpes simplex virus type 1 by ammonium chloride and chloroquine. Virology 1984;138:332–5.

[42] Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009;53:3416–21.

[43] Blau D, Holmes K. Human coronavirus HCoV-229E enters susceptible cells via the endocytic pathway. In: Lavi E, Weiss SR, Hingley ST, editors. The nidoviruses (coronaviruses and arteriviruses). New York, NY: Kluwer; 2001. p. 193–7.

[44] Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res 2008;77:150–2. doi: 10.1016/j.antiviral.2007.10.011.

[45] Shen L, Yang Y, Ye F, Liu G, Desforges M, Talbot PJ, et al. Safe and sensitive antiviral screening platform based on recombinant human coronavirus OC43 expressing the luciferase reporter gene. Antimicrob Agents Chemother 2016;60:5492–503. doi: 10.1128/AAC.00814-16.

[46] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014;58:4875–84. doi: 10.1128/AAC.03011-14.

[47] Mo Y, Fisher D. A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother 2016;71:3340–50.

[48] Burkard C, Verheije MH, Wicht O, van Kasteren SI, van Kuppeveld FJ, Haagmans BL, et al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog 2014;10:e1004502.

[49] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell Res 2020;30:269–71. doi: 10.1038/s41422-020-0282-0.
[50] Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020 Feb [Epub ahead of print]. doi: 10.5582/bst.2020.01047.

[51] Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:E019. doi: 10.3760/cma.j.issn.1001-0939.2020.0019.

[52] Bernstein HN. Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292–6.

[53] Ratliff NB, Estes ML, Myles JL, Shirey EK, McMahon JT. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987;316:191–3.

[54] Cubero GJ, Rodriguez Reguero JJ, Rojo Ortega JM. Restrictive cardiomyopathy caused by chloroquine. Br Heart J 1993;69:451–2.

[55] Harrison C. Coronavirus puts drug repurposing on the fast track. Nature Biotechnology 2020 Feb 27. doi: 10.1038/d41587-020-00003-1.

[56] Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 2004;43:4538–47.

[57] Varki A. Sialic acids as ligands in recognition phenomena. FASEB J 1997;11:248–55.

[58] Olofsson S, Kumlin U, Dimock K, Arenberg N. Avian influenza and sialic acid receptors: more than meets the eye? Lancet Infect Dis 2005;5:184–8.

[59] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69. doi: 10.1186/1743-422X-2-69.

[60] Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010;4:e785. doi: 10.1371/journal.pntd.0000785.

[61] Gay B, Bernard E, Solignat M, Chazal N, Devaux C, Briant L. pH dependent entry of Chikungunya virus into Aedes albopictus cells. Infect Genet Evol 2012;12:1275–81. doi: 10.1016/j.meegid.2012.02.003.

[62] Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004;78:5642–50. doi: 10.1128/JVI.78.11.5642-5650.2004.
[63] Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2008;18:290–301. doi: 10.1038/cr.2008.15.

[64] Cassell S, Edwards J, Brown DT. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J Virol 1984;52:857–64.

[65] Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndrome 1996;35:223–32.

[66] Harley CA, Dasgupta A, Wilson DW. Characterization of herpes simplex virus-containing organelles by subcellular fractionation: role for organelle acidification in assembly of infectious particles. J Virology 2001;75:1236–51.

[67] Klumperman J, Locker JK, Meijer A, Horzinek MC, Geuze HJ, Rottier PJ. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol 1994;68:6523–34.

[68] Perrier A, Bonnin A, Desmarets L, Danneels A, Goffard A, Rouillé Y, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J Biol Chem 2019;294:14406–21.

[69] Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 2004;303:1529–31.

[70] Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med 2005;202:817–28.

[71] Garulli B, Di Mario G, Sciaraffia E, Accapezzato D, Barnaba V, Castrucci MR. Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 2013;31:1717–24. doi: 10.1016/j.vaccine.2013.01.037.

[72] Steiz M, Valbracht J, Quach J, Lotz M. Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 2003;23:477–84. doi: 10.1023/B:JOCI.0000010424.41475.17.

[73] Briant L, Robert-Hebmann V, Acquaviva C, Pelchen-Matthews A, Marsh M, Devaux C. The protein tyrosine kinase p56lck is required for triggering NF-κB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4. J Virol 1998;72:6207–14.

[74] Fuld H, Horwich L. Treatment of rheumatoid arthritis with chloroquine. Br Med J 1958,15:1199–201. doi: 10.1136/bmj.2.5106.1199.
[75] Mackenzie AH. Antimalarial drugs for rheumatoid arthritis. Am J Med 1983;75:48–58.

[76] Sharma TS, Do EJ, Wasko MCM. Anti-malarials: are there benefits beyond mild disease? Curr Treat Options Rheumatol 2016;2:1–12. doi: 10.1007/s40674-016-0036-9.

[77] Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine evels in systemic lupus erythematosus patients. Lupus 2006;15:268–75.

[78] Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998;55:1248–54.

[79] Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 2006;45:703–10.

[80] Picot S, Peyron F, Donadille A, Vuillez J-P, Barbe G, Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993;80:127–33.

[81] Jeong JY, Jue DM. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997;158:4901–7.

[82] Zhu X, Ertel W, Ayala A, Morrison MH, Perrin MM, Chaudry IH. Chloroquine inhibits macrophage tumour necrosis factor-α mRNA transcription. Immunology 1993;80:122–6.

[83] Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534–40. doi: 10.4049/jimmunol.165.3.1534.

[84] Jeong JY, Choi JW, Jeon KI, Jue DM. Chloroquine decreases cell surface expression of tumour necrosis factor receptors in human histiocytic U-937 cells. Immunology 2002;105:83–91. doi: 10.1046/j.0019-2805.2001.01339.x.

[85] Review Karion et al. (2020). https://doi.org/10.5194/essd-2019-206-rec2 Sola, I. (2020). Estrategias para controlar al nuevo coronavirus SARS-Cov https://doi.org/10.18567/sebbmdiv_actu.2020.03.1

[86] Frisk-Holmberg, M., Bergqvist, Y., & Englund, U. (1983). Chloroquine intoxication [letter]. British Journal of Clinical Pharmacology, 15(4), 502-503. https://doi.org/10.1111/j.1365-2125.1983.tb01540. Review Karion et al. (2020). https://doi.org/10.5194/essd-2019-206-rec2

[87] Miller, W., & Miller, A. E. (1984). American National Election Study, 1972. ICPSR Data Holdings. https://doi.org/10.3886/icpsr07010
[88] Alcaraz, L., & Et al., E. A. (2004). Novel P2X7 Receptor Antagonists. ChemInform, 35(10). https://doi.org/10.1002/chin.200410113

[89] Alexander, P. (2011). Paton, Alan Stewart. African American Studies Center. https://doi.org/10.1093/acref/9780195301731.013.49746

[90] System design schematics from: (A) Son et al. (2010); (B) Lau et al. (2010); (C) Fujiwara et al. (2011); and (D) Gjerlufsen et al. (2011). (n.d.). https://doi.org/10.7717/peerjcs.88.

[91] Parker, C. T., Taylor, D., & Garrity, G. M. (2003). Exemplar Abstract for Roseovarius crassostreae Boettcher et al. 2005, Aliiroseovarius crassostreae (Boettcher et al. 2005) Park et al. 2015. The Names for Life Abstracts. https://doi.org/10.1601/ex.9525.

[92] Chua, K., Laurent, F., Coombs, G., Grayson, M. L., & Howden, B. P. (2011). Reply to De Angelis et al. Clinical Infectious Diseases, 52(12), 1472-1472. https://doi.org/10.1093/cid/cir250.

[93] Moulis, A., & Roques, M. (2018). Subjectivation et fantasmes de transmission à l’épreuve du secret. Psychologie clinique et projective, 24(1), 147. https://doi.org/10.3917/pcp.024.0147.

[94] Moulis, A., & Roques, M. (2018). Subjectivation et fantasmes de transmission à l’épreuve du secret. Psychologie clinique et projective, 24(1), 147. https://doi.org/10.3917/pcp.024.0147.

[95] Chauhan, A., Tikoo, A., Kapur, A. K., & Singh, M. (2007). The taming of the cell penetrating domain of the HIV Tat: Myths and realities. Journal of Controlled Release, 117(2), 148-162. https://doi.org/10.1016/j.jconrel.2006.10.031

[96] Wang PH, Cheng Y. Increasing host cellular receptor—angiotensinconverting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019- nCoV infection. bioRxiv 2020 Feb 27. doi: 10.1101/2020.02.24.963348.

[97] Li R, Qiao S, Zhang G. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. J Infect 2020 Feb 21 [Epub ahead of print]. doi: 10.1016/j.jinf.2020.02.013.

[98] Zeng Q, Langereis MA, van Vliet ALW, Huizinga EG, de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 2008;105:9065–9.

[99] Bakkers MJG, Lang Y, Feistsma LJ, Hulswit RJG, de Poot SAH, van Vliet ALW, et al. Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity. Cell Host Microbe 2017;21:356–66. doi: 10.1016/j.chom.2017.02.008.
Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, et al. Different host cell proteases activate the SARS-coronavirus spikeprotein for cell–cell and virus–cell fusion. Virology 2011;413:265–74. doi: 10.1016/j.virol.2011.02.020.

Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrobial Agents 2020 Mar 4:105932. doi: 10.1016/j.ijantimicag.2020.105932.

Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies to control emerging coronaviruses. Nat Rev Microbiol 2013;11:836–48.

Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol 2014;88:13221–30.

Collins AR. HLA class I antigen serves as a receptor for human coronavirus OC43. Immunol Invest 1993;22:95–103.

Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A 2014;111:6756–61.

Vlasak R, Luytjes W, Spaan W, Palese P. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci U S A 1988;85:4526–9.

Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu QK, et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol 2015;89:7202–13.

Chan CM, Lau SKP, Woo PCY, Tse H, Zheng BJ, Chen L, et al. Identification of major histocompatibility complex class I C molecule as an attachment factor that facilitates coronavirus HKU1 spike-mediated infection. J Virol 2009;83:1026–35.

Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A 2014;111:15214–9.

Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020 Jan 26. doi: 10.1101/2020.01.26.919985

Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfeflerle S, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011;85:4122–34.
[112] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23. doi: 10.1007/978-1-4939-2438-7_1.